JPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $115.00 (from $125.00).

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $119.87 yesterday.